Logo1

Zastrozhin MS., Sorokin AS., Agibalova AV., Grishina EA., Antonenko AР., Rozochkin IN., Duzhev DV., Skryabin VY., Galaktionova TE., Barna IV., Orlova AV., Aguzarov AD., Savchenko LM., Bryun EA., Sychev DA.
Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers.
Human Psychopharmacology: Clinical and Experimental.2018;e2677, 8.

скачать материал

 



DOI: 10.1002/hup.2677

Просмотров: 8958

Sychev D, Shikh N, Morozova T, Grishina E, Ryzhikova K, Malova E.
Effects of ABCB1 rs1045642 polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I–II hypertension.
Pharmacogenomics and Personalized Medicine 2018, 11:157-165.
DOI https://doi.org/10.2147/PGPM.S158401

 

скачать материалскачать материал

Просмотров: 9648

Fedorinov DS, Mirzaev KB, Mustafina VR, Sychev DA, Maximova NR, Chertovskikh JV, Popova NV, Tarabukina SM, Rudykh ZA.
Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA).
Drug Metab Pers Ther. 2018 Oct 16. pii: /j/dmdi.ahead-of-print/dmpt-2018-0015/dmpt-2018-0015.xml.

doi: 10.1515/dmpt-2018-0015.

скачать материал

Просмотров: 8246

Zastrozhin MS, Antonenko AP, Nesterenko EV, Seyfullaeva LI, Mustafina VR, Esakova AP, Grishina EA, Sorokin AS, Skryabin VY, Savchenko LM, Bryun EA, Sychev DA.
Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder.
Drug Metab Pers Ther. 2018 Oct 16.
doi: 10.1515/dmpt-2018-0019.

скачать материал

Просмотров: 8993

DOI https://doi.org/10.2147/PGPM.S185056

Corrigendum!

Sychev DA, Levanov AN, Shelekhova TV, Bochkov PO, Denisenko NP, Ryzhikova KA, Mirzaev KB, Grishina EA, Gavrilov MA, Ramenskaya GV, Kozlov AV, Bogoslovsky T. The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty. Pharmacogenomics and Personalized Medicine.2018:11;127—137.

DOI https://doi.org/10.2147/PGPM.S169277

скачать материал

Просмотров: 8971
  1. Mirzaev KB., Rytkin E., Ryzhikova KA., et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabolism and Personalized Therapy 2018.
  2. Zastrozhin MS, Grishina EA, Denisenko NP, et al. Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. Pharmacogenomics and Personalized Medicine 2018:11;1
  3. Denisenko NP, Sychev DA, Sizova ZM, et al. CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. 2018:11;107—112.
  4. Fedorinov DS, Mirzaev KB, Ivashchenko DV, et al. Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). Drug Metab Pers Ther. 2018 May 8.